405 filings
Page 6 of 21
6-K
vcz9l
12 Oct 18
Primary Document
4:50pm
F-1MEF
wu7uh9zl
12 Oct 18
Registration statement to add securities to prior F-1 registration
6:06am
EFFECT
4kjf20
12 Oct 18
Notice of effectiveness
12:15am
F-1/A
0hyb pvo1zd2qbai
11 Oct 18
Registration statement (foreign) (amended)
6:41am
424B3
enucgupbm186 4z
11 Oct 18
Prospectus supplement
6:34am
CORRESP
mfou8767
11 Oct 18
Correspondence with SEC
12:00am
CORRESP
cqhy366 57a
11 Oct 18
Correspondence with SEC
12:00am
6-K
ld0rh
10 Oct 18
Intellipharmaceutics Announces Completion of the Clinical Component of Category 2 and 3 Human Abuse Liability Studies for Oxycodone ER
9:57pm
FWP
c9gbxm
5 Oct 18
Free writing prospectus
5:26pm
424B3
07ad4
5 Oct 18
Prospectus supplement
7:15am
6-K
khe0zyib
5 Oct 18
Primary Document
7:07am
F-1/A
xga2qmgm83vb8h758zc
4 Oct 18
Registration statement (foreign) (amended)
9:47pm
424B3
mgv9iu6il
1 Oct 18
Prospectus supplement
12:00am
UPLOAD
l1eaym mifcm
1 Oct 18
Letter from SEC
12:00am
6-K
woyoz0
1 Oct 18
Intellipharmaceutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Also Receives Requested Extension from Nasdaq Panel
12:00am
6-K
0dsuiu6zh4osu8mm
21 Sep 18
Primary Document
4:41pm
SC 13D/A
oau5exw42l9zjxa20
21 Sep 18
Intellipharmaceutics International Inc.
4:30pm
F-1
gm2kd8mt1dlp
20 Sep 18
Registration statement (foreign)
5:24pm
424B3
jio63a8jjde z51
13 Sep 18
Prospectus supplement
12:00am
6-K
jtx1y 5mp
13 Sep 18
Primary Document
12:00am